Company / Revenue
Taysha Gene Therapies, Inc. Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$9.8M
FY2025
5-year range
$2.5M / $15.5M
FY2022-FY2025
Trend
-36.7%
vs FY2024
Sector context
#136 of 155
Health Care
What the data says
Taysha Gene Therapies, Inc.'s revenue of $10M is lower than 88% of companies in the Health Care sector (FY2025). Improved from $3M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 3-year CAGR of +57.5%.
Improved from $3M to $10M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +57.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 155This company $9.8M Sector average $4.5B
▼
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +57.5%, indicating consistent growth.
- In FY2025, revenue decreased 36.7% year-over-year.
- Ranks #136 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.8M | -36.7% |
| FY2024 | $15.5M | +517.5% |
| FY2023 | $2.5M | +0.0% |
| FY2022 | $2.5M | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026